<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04330079</url>
  </required_header>
  <id_info>
    <org_study_id>ENTRY trial</org_study_id>
    <nct_id>NCT04330079</nct_id>
  </id_info>
  <brief_title>Effects of dapaglifloziN Therapy on Myocardial Perfusion Reserve in Prediabetic Patients With Stable coronarY Artery Disease</brief_title>
  <official_title>Effects of dapaglifloziN Therapy on Myocardial Perfusion Reserve in Prediabetic Patients With Stable coronarY Artery Disease (ENTRY Trial)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CHEOL WHAN LEE, M.D., Ph.D</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the effects of dapagliflozin therapy on&#xD;
      myocardial perfusion reserve (MPR) using dynamic SPECT examination in prediabetic patients&#xD;
      with stable CAD.&#xD;
&#xD;
      Dapagliflozin therapy versus lifestyle modification improves myocardial perfusion reserve in&#xD;
      prediabetic patients with stable CAD.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 21, 2020</start_date>
  <completion_date type="Anticipated">February 28, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change in global myocardial perfusion reserve (MPR) index</measure>
    <time_frame>6months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percent change in regional myocardial perfusion reserve (MPR) index</measure>
    <time_frame>6months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>absolute changes in global MPR index</measure>
    <time_frame>6months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>absolute changes in regional MPR index</measure>
    <time_frame>6months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in body weight</measure>
    <time_frame>6months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in blood pressure(systolic, diastolic both )</measure>
    <time_frame>6months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Prediabetic State</condition>
  <arm_group>
    <arm_group_label>Dapagliflozin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Lifestyle modification</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin 10mg</intervention_name>
    <description>Dapagliflozin 10mg once daily for 6 months.</description>
    <arm_group_label>Dapagliflozin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Lifestyle modification</intervention_name>
    <description>lifestyle modification (diet and exercise) for 6 months</description>
    <arm_group_label>Lifestyle modification</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Men or women at least 18 years of age&#xD;
&#xD;
          2. Prediabetes by ADA criteria (fasting glucose 100-125mg/dl, or HbA1C 5.7-6.4%)&#xD;
&#xD;
          3. Stable coronary artery disease&#xD;
&#xD;
          4. Global myocardial perfusion reserve (MPR) index &lt; 2.0&#xD;
&#xD;
          5. The patient or guardian agrees to the study protocol and the schedule of clinical and&#xD;
             dynamic SPECT follow-up, and provides informed, written consent, as approved by the&#xD;
             appropriate Institutional Review Board/Ethical Committee of the respective clinical&#xD;
             site.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Contraindications to dapagliflozin&#xD;
&#xD;
          2. Significant renal disease manifested by eGFR&lt;30 ml/min/1.73mÂ²&#xD;
&#xD;
          3. Unstable or rapidly progressing renal disease&#xD;
&#xD;
          4. Acute coronary syndrome, or any other major cardiovascular events within the previous&#xD;
             6 months&#xD;
&#xD;
          5. Stent placement, or coronary artery bypass graft surgery within the previous 6 months&#xD;
&#xD;
          6. Planned revascularization within 6 months&#xD;
&#xD;
          7. Significant disease (diameter stenosis &gt;70% by coronary CT angiography) in major&#xD;
             epicardial coronary arteries&#xD;
&#xD;
          8. Heart failure requiring loop diuretics&#xD;
&#xD;
          9. Hepatic disease or biliary tract obstruction, or significant hepatic enzyme elevation&#xD;
             (ALT or AST &gt; 3 times upper limit of normal).&#xD;
&#xD;
         10. Contraindication to adenosine stress test&#xD;
&#xD;
         11. Current treatment for the active cancer&#xD;
&#xD;
         12. Women of child bearing potential who are not willing to use a medically accepted&#xD;
             method of contraception. Patient's pregnancy confirmed by positive pregnancy test, or&#xD;
             breast-feeding.&#xD;
&#xD;
         13. Expected life expectancy &lt; 1 year&#xD;
&#xD;
         14. Any clinically significant abnormality identified at the screening visit, physical&#xD;
             examination, laboratory tests which, in the judgment of the investigator, would&#xD;
             preclude safe completion of the study.&#xD;
&#xD;
         15. Unwillingness or inability to comply with the procedures described in this protocol.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cheol Whan Lee, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cheol Whan Lee, MD, PhD</last_name>
    <phone>82230103150</phone>
    <email>cheolwlee@amc.seoul.kr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cheol whan Lee, MD, PhD</last_name>
      <phone>+82230103150</phone>
      <email>cheolwlee@amc.seoul.kr</email>
    </contact>
    <investigator>
      <last_name>Cheol Whan Lee, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>March 30, 2020</study_first_submitted>
  <study_first_submitted_qc>March 30, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 1, 2020</study_first_posted>
  <last_update_submitted>December 21, 2020</last_update_submitted>
  <last_update_submitted_qc>December 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>CHEOL WHAN LEE, M.D., Ph.D</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Dapagliflozin</keyword>
  <keyword>Lifestyle modification</keyword>
  <keyword>Myocardial perfusion reserve</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Prediabetic State</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dapagliflozin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

